Saluda Medical Inc · ASX:SLD
Saluda Medical — Q4 FY26 Earnings Presentation
11 slides from Saluda Medical's earnings presentation, Jul 29, 2026
Slide 1: Saluda Medical Q4 FY26 Update
For personal use only Saluda Medical Q4 FY26 Update July 29th, 2026 Weare on a Mission to Transform Patients’ Lives with Revolutionary Neural-Sensing Technology
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer THIS DOCUMENT AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIB
Slide 3: Spinal Cord Stimulation (SCS) is an Established Market
Spinal Cord Stimulation (SCS) is an Established Market SCS represents a substantial opportunity which remains significantly underserved For personal use only Annual cost of chronic pain in ~24% of American Adults2 US exceed costs of heart disease, cancer and diabetes1 have chronic pain ~6% Estimated
Slide 4: Traditional Fixed Dose SCS for Chronic Pain
Traditional Fixed Dose SCS for Chronic Pain Well-established therapy for the treatment of chronic neurological pain Standard SCS Stimulation with no variation… For personal use only Traditional Fixed Dose SCS Patient adjusts stimulation with 4 remote control 30+ times per day1 SCS leads are implante
Slide 5: Saluda Medical’s Personalised, Closed-Loop Technology
Saluda Medical’s Personalised, Closed-Loop Technology Saluda Medical’s three major breakthroughs represent a paradigm shift in SCS therapy Evoke adjusts the level of stimulation in real time… For personal use only 1 Stimulati Measures the nerve’s response on to stimulation 2 Sitting Leaning Walk Sup
Slide 6: Breakthrough Clinical Data, Patient Outcomes & Therapy Burden
Breakthrough Clinical Data, Patient Outcomes & Therapy Burden Backed by the world’s only double-blinded trial in SCS conducted over 3 years For personal use only Closed-loop system reads, measures OUTCOME HIGHLIGHTS and responds to patient-specific needs Ensures accurate physiologic dosing in real-t
Slide 7: Lower Reprogramming Rates | Real World Experience
Lower ReprogrammingRates | Real World Experience Less than one reprogramming visits after 12 months1 6.0 7 6.0 Visits per year, per Patient For personal use only Average Visits2 with Standard SCS2 6 5 4 3.1 Average Visits <1 visit per year after the first 12 months 3 1.5 2 2.9 Average Visits 89% Ave
Slide 8: Q4 FY26 Quarterly Activity Report
Q4 FY26 Quarterly Activity Report ASX announcement highlights As per standalone ASX announcement dated 29 July 2026 For personal use only ▪ FY26 full-year revenue ▪ US$90.2m, +28% vs prior corresponding period (pcp) ▪ Exceeded guidance of US$87.0m ▪ Q4 FY26 revenue ▪ Accelerating global growth: US$2
Slide 9: Revenue and select US commercial metrics
Q4 FY26 Quarterly Activity Report Revenue and select US commercial metrics QUARTERLY REVENUE TREND(US$M)1 MOST RECENT QUARTERLY COMMERCIAL PERFORMANCE1 For personal use only ASX IPO $27.0M Q4 Q4 Growth Full Year Full Year Growth FY26 FY25 vs. PCP FY26 FY25 vs. PCP US Int'l $23.8M US Revenue ($m) 18.
Slide 10: Paddle Lead: Entering the Orthopaedic / Neurosurgeon Market
Paddle Lead: Entering the Orthopaedic / Neurosurgeon Market ORTHOPAEDIC / NEUROSURGEONS CURENTLY ACCOUNT FOR 30% OF U.S. MARKET3 PADDLE LAUNCH For personal use only Early stage of • Completed FDA approval June 2026 2024 U.S. Market Size1 penetration in high volume ASC sub segment • Limited commercia
Slide 11: Everything Changes. This Changes Everything.
For personal use only EVERYTHING CHANGES. THIS CHANGES EVERYTHING. Therapy as Dynamic as Life.